Acne is caused by an infection that leads to inflammation of the hair follicles. It usually begins in the teenage years but can persist until the 30s and 40s.
The global acne therapeutics market can be segmented into therapeutics and other (non-drug) treatments. The therapeutics segment includes antibiotics, retinoids, combination medications, anti-inflammatory, and hormones. Non-drug treatments include laser and light therapy, cosmetic procedures and acne scar treatment.
Limitations of current treatments include:
• bacterial resistance, and
• serious side effects such as skin irritation, burning sensation, erythema and scaling
Our CoSensia is an RNA-based anti-acne skincare product with a core active ingredient that comprises double stranded RNAs (dsRNAs). Double-stranded RNAs (dsRNAs) increase anti-inflammation cytokines (IL-4 etc.) and activate the natural immune responses which suppress inflammation process. Meanwhile, dsRNAs can directly inhibit acne pathogens -- Propionibacterium acnes. Other related bacteria including, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus are prohibited by antibacterial ingredients in the CoSensia product. These cofactors can effectively eliminate or mitigate acne.
From a small pilot user trial (conducted in 2013 in China) of 47 individuals (young adults) with acne vulgaris, CoSensia was demonstrated to be very effective in relieving 38 users from acne (80%).
The results from this study demonstrates that CoSensia has the potential to address a significant unmet medical need in the treatment of acne.
• Latest generation of anti-acne procduct
• RNA to stimulate cellular immunity
• Nourishing and soothing for the skin
• Low drug resistance